Xenetic Biosciences releases updated corporate presentation highlighting XCART CAR T program and upcoming milestones

Xenetic Biosciences, Inc.

XCART targets tumor-specific antigens independent of CD19, advancing toward a Phase 1 study.
Cash runway expected to fund the company through an IND filing for XCART.
Corporate presentation cites potential for increased efficacy, safety, and tolerability over approved CAR T therapies.
Expects CAR T therapies to hold significant revenue share by 2026 with a drop in Rituxan use.
Plans to leverage outsourced relationships and academic collaborations for clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.